Related references
Note: Only part of the references are listed.Response to: 'Correspondence on 'Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial'' by Cai and Peng response
Anna Molto et al.
ANNALS OF THE RHEUMATIC DISEASES (2023)
Tumor Necrosis Factor Inhibitors Reduce Spinal Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: A Longitudinal Analysis from the Alberta Prospective Cohort
Alexandre Sepriano et al.
ARTHRITIS & RHEUMATOLOGY (2021)
Treat-to-target in axial spondyloarthritis - what about physical function and activity?
Juergen Braun et al.
NATURE REVIEWS RHEUMATOLOGY (2021)
Structural changes in the sacroiliac joint on MRI and relationship to ASDAS inactive disease in axial spondyloarthritis: a 2-year study comparing treatment with etanercept in EMBARK to a contemporary control cohort in DESIR
Walter P. Maksymowych et al.
ARTHRITIS RESEARCH & THERAPY (2021)
Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence
Bon San Koo et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Outcomes and treatment responses, including work productivity, among people with axial spondyloarthritis living in urban and rural areas: a mixed-methods study within a national register
Rosemary J. Hollick et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate
Denis Poddubnyy et al.
BMJ OPEN (2020)
Impact of Tumor Necrosis Factor Inhibitor Versus Nonsteroidal Antiinflammatory Drug Treatment on Radiographic Progression in Early Ankylosing Spondylitis: Its Relationship to Inflammation Control During Treatment
Jun Won Park et al.
ARTHRITIS & RHEUMATOLOGY (2019)
The European Map of Axial Spondyloarthritis: Capturing the Patient Perspectivean Analysis of 2846 Patients Across 13 Countries
Marco Garrido-Cumbrera et al.
CURRENT RHEUMATOLOGY REPORTS (2019)
2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Michael M. Ward et al.
ARTHRITIS & RHEUMATOLOGY (2019)
Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states
Pedro M. Machado et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Functional relevance of radiographic spinal progression in axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort
Denis Poddubnyy et al.
RHEUMATOLOGY (2018)
Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial
Desiree van der Heijde et al.
ARTHRITIS RESEARCH & THERAPY (2018)
TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort
Christoph Molnar et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Treat to Target in Axial Spondyloarthritis: What Are the Issues?
Abhijeet Danve et al.
CURRENT RHEUMATOLOGY REPORTS (2017)
Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations
Sofia Ajeganova et al.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE (2017)
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
Desiree van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis
Proton Rahman et al.
BMJ OPEN (2016)
Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort
Sofia Ramiro et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
The classification and diagnostic criteria of ankylosing spondylitis
Siba P. Raychaudhuri et al.
JOURNAL OF AUTOIMMUNITY (2014)
Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores
Pedro Machado et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Thresholds of Patient-Reported Outcomes That Define the Patient Acceptable Symptom State in Ankylosing Spondylitis Vary Over Time and by Treatment and Patient Characteristics
Walter P. Maksymowych et al.
ARTHRITIS CARE & RESEARCH (2010)
Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis
C. Lukas et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine
R. Landewe et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Development and validation of the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index
W. P. Maksymowych et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: Data from a randomized controlled trial
Maxime Dougados et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Evaluation and validation of the patient acceptable symptom state (PASS) in patients with ankylosing-spondylitis
Walter P. Maksymowych et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2007)
What is the most appropriate radiologic scoring method for ankylosing spondylitis?
AJB Wanders et al.
ARTHRITIS AND RHEUMATISM (2004)
Share Paper
